Korean J Gastroenterol.  2012 Dec;60(6):362-367. 10.4166/kjg.2012.60.6.362.

Effect of Proton Pump Inhibitor in Patients with Acute Pancreatitis: Pilot Study

• Yoo JH
• Kwon CI
• Yoo KH
• Yoon H
• Kim WH
• Ko KH
• Hong SP
• Park PW

• KMID: 1773072
• DOI: http://doi.org/10.4166/kjg.2012.60.6.362

Abstract

BACKGROUND/AIMS
Oxygen free radicals play an important role in acute pancreatitis. Pantoprazole as a proton pump inhibitor (PPI) has pancreatic anti-secretory effect and a pronounced inhibitory reactivity towards hydroxyl radicals. The objective of the study was to investigate the effect of pantoprazole on the course of acute pancreatitis.
METHODS
We conducted a prospective randomized trial involving 40 patients with acute pancreatitis. Patients were divided into two groups. One group received PPI and the other group did not receive PPI. In the PPI group, patients received pantoprazole 40 mg intravenously twice a day for fasting time, and then 40 mg orally twice a day until discharge.
RESULTS
There were no significant differences in baseline characteristics and laboratory markers between two groups. In the pantoprazole group, mean hospital stay was 7.4 days, time to start oral intake was 69.0 hours, and time to pain relief was 59.7 hours. Acute physiology and chronic health evaluation (APACHE) II score was 3.15 at admission day and 2.35 at discharge. On the other hand, in the non-pantoprazole group, mean hospital stay was 7.6 days, time taken to start oral intake was 71.4 hours, and time taken to pain relief was 61.8 hours. APACHE II score was 4.4 at admission and 2.85 at discharge. However, there were no significant differences between two groups.
CONCLUSIONS
Treatment with pantoprazole did not have influence on the clinical course of acute pancreatitis. But, considering it was a pilot study, large scale prospective trials will be needed.

Keyword

Pancreatitis; Proton pump inhibitors; Oxidative stress

MeSH Terms

2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
APACHE
Acute Disease
Adolescent
Adult
Aged
Aged, 80 and over
Alcohol Drinking
Eating
Female
Humans
Length of Stay
Male
Middle Aged
Pain Management
Pancreatitis/*drug therapy/etiology
Pilot Projects
Prospective Studies
Proton Pump Inhibitors/*therapeutic use
Young Adult
2-Pyridinylmethylsulfinylbenzimidazoles
Proton Pump Inhibitors

Reference

1. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med. 1994. 330:1198–1210.

2. Weber CK, Adler G. From acinar cell damage to systemic inflammatory response: current concepts in pancreatitis. Pancreatology. 2001. 1:356–362.

3. Schoenberg MH, Büchler M, Gaspar M, et al. Oxygen free radicals in acute pancreatitis of the rat. Gut. 1990. 31:1138–1143.

4. Tsai K, Wang SS, Chen TS, et al. Oxidative stress: an important phenomenon with pathogenetic significance in the progression of acute pancreatitis. Gut. 1998. 42:850–855.

5. Rau B, Poch B, Gansauge F, et al. Pathophysiologic role of oxygen free radicals in acute pancreatitis: initiating event or mediator of tissue damage? Ann Surg. 2000. 231:352–360.

6. Park BK, Chung JB, Lee JH, et al. Role of oxygen free radicals in patients with acute pancreatitis. World J Gastroenterol. 2003. 9:2266–2269.

7. Simon WA, Sturm E, Hartmann HJ, Weser U. Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol. 2006. 71:1337–1341.

8. Hackert T, Tudor S, Felix K, et al. Effects of pantoprazole in experimental acute pancreatitis. Life Sci. 2010. 87:551–557.

9. Vakil N, van Zanten SV, Kahrilas P, et al. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006. 101:1900–1920.

10. Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. Radiology. 1990. 174:331–336.

11. Siriwardena AK, Mason JM, Balachandra S, et al. Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis. Gut. 2007. 56:1439–1444.

12. Morimoto T, Noguchi Y, Sakai T, Shimbo T, Fukui T. Acute pancreatitis and the role of histamine-2 receptor antagonists: a meta-analysis of randomized controlled trials of cimetidine. Eur J Gastroenterol Hepatol. 2002. 14:679–686.

13. Eland IA, Alvarez CH, Stricker BH, Rodríguez LA. The risk of acute pancreatitis associated with acid-suppressing drugs. Br J Clin Pharmacol. 2000. 49:473–478.

14. Blomgren KB, Sundström A, Steineck G, Genell S, Sjöstedt S, Wiholm BE. A Swedish case-control network for studies of drug-induced morbidity--acute pancreatitis. Eur J Clin Pharmacol. 2002. 58:275–283.

15. Lancashire RJ, Cheng K, Langman MJ. Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. Aliment Pharmacol Ther. 2003. 17:887–893.

16. Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut. 1992. 33:617–621.

17. Fornai M, Natale G, Colucci R, et al. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol. 2005. 372:79–87.

18. Dattilo M, Figura N. Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors. J Clin Gastroenterol. 1998. 27:Suppl 1. S163–S169.

19. Lim YS, Ryu JK, Lee HC, Kim YT, Yoon YB, Kim CY. Comparison of etiological and prognostic factors in acute necrotizing pancreatitis. Korean J Gastroenterol. 1997. 29:667–676.

20. Ahn SK, Kim WH, Chung JP, et al. Early prediction of the severity in patient with acute pancreatitis by stepwise discriminant analysis. Korean J Med. 1994. 47:493–502.

21. Lee BJ, Kim CD, Jung SW, et al. Analysis of the factors that affect the mortality rate in severe acute pancreatitis. Korean J Gastroenterol. 2008. 51:25–33.